Literature DB >> 23030045

Ischemia/reperfusion-induced renal failure in rats as a model for evaluating cell therapies.

Hung-Jen Wang1, Adam Varner, Tamer AbouShwareb, Anthony Atala, James J Yoo.   

Abstract

Chronic renal failure is a devastating disease that leads to a multitude of complications. Cell therapy has emerged as a potential treatment modality for renal failure. However, efficacy testing on systemic renal function has been challenging due to the limited availability of reliable models that are fully characterized. In this study, we investigated the possibility of using renal ischemia/reperfusion (I/R) injury as a viable model for testing cell therapies. We examined functional and pathological changes in rat kidneys that were exposed to different ischemia times. Male Lewis rats were divided into five groups. Renal failure was induced by clamping both renal pedicles for combinations of 60, 75, and 90 min, followed by reperfusion. Age-matched healthy rats served as controls. Blood was collected at regular intervals for serum chemistry, and kidneys were harvested at the same intervals for histomorphological assessment. Serum creatinine levels of the animals with I/R injury increased significantly after 3 days and returned to normal levels at 4 weeks. Histologically, kidney tissue showed progressive glomerular and tubular deterioration with varying degrees of fibrosis. Animals exposed to 75- and 90-min ischemia combination times consistently generated more severe injury than the 60-min ischemia period. However, these groups resulted in a high mortality rate. A model in which one kidney is exposed to a shorter ischemia time (60 or 90 min) resulted in sustained renal damage with a lower mortality rate. This study shows that kidneys exposed to I/R result in renal tissue damage as well as decreased renal function. This model can be used to study both the short-term and longer-term effects of kidney disease by varying the length of the ischemic time. In particular, the use of longer ischemic times (75 and 90 min) could be used to study new therapies for acute renal disease, whereas shorter ischemic times (60 min) could be used to study therapies for chronic renal insufficiency.

Entities:  

Mesh:

Year:  2012        PMID: 23030045     DOI: 10.3109/0886022X.2012.725292

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  8 in total

1.  The Effect of the Antioxidant Drug "U-74389G" on Creatinine Levels during Ischemia Reperfusion Injury in Rats.

Authors:  Constantinos Tsompos; Constantinos Panoulis; Konstantinos Toutouzas; George Zografos; Apostolos Papalois
Journal:  Curr Urol       Date:  2016-05-20

Review 2.  Preconditioning against renal ischaemia reperfusion injury: the failure to translate to the clinic.

Authors:  Dermot O'Kane; Graham S Baldwin; Damien M Bolton; Joseph J Ischia; Oneel Patel
Journal:  J Nephrol       Date:  2019-01-11       Impact factor: 3.902

Review 3.  Cell-based therapy for kidney disease.

Authors:  Hyun Chul Chung; In Kap Ko; Anthony Atala; James J Yoo
Journal:  Korean J Urol       Date:  2015-05-27

4.  Protective effect of zinc preconditioning against renal ischemia reperfusion injury is dose dependent.

Authors:  Kenny Rao; Kapil Sethi; Joseph Ischia; Luke Gibson; Laurence Galea; Lin Xiao; Mildred Yim; Mike Chang; Nathan Papa; Damien Bolton; Arthur Shulkes; Graham S Baldwin; Oneel Patel
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

5.  Volume incompliance and transfusion are essential for transfusion-associated circulatory overload: a novel animal model.

Authors:  Robert B Klanderman; Joachim J Bosboom; Adrie A W Maas; Joris J T H Roelofs; Dirk de Korte; Robin van Bruggen; Jaap D van Buul; Coert J Zuurbier; Denise P Veelo; Markus W Hollmann; Margreeth B Vroom; Nicole P Juffermans; Bart F Geerts; Alexander P J Vlaar
Journal:  Transfusion       Date:  2019-11-07       Impact factor: 3.157

6.  Estradiol Ameliorates Acute Kidney Ischemia-Reperfusion Injury by Inhibiting the TGF-βRI-SMAD Pathway.

Authors:  Lian Ren; Fang Li; Ziyang Di; Yan Xiong; Shichen Zhang; Qing Ma; Xiaoen Bian; Zhiquan Lang; Qifa Ye; Yanfeng Wang
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

Review 7.  Imaging technologies for monitoring the safety, efficacy and mechanisms of action of cell-based regenerative medicine therapies in models of kidney disease.

Authors:  Jack Sharkey; Lauren Scarfe; Ilaria Santeramo; Marta Garcia-Finana; Brian K Park; Harish Poptani; Bettina Wilm; Arthur Taylor; Patricia Murray
Journal:  Eur J Pharmacol       Date:  2016-07-01       Impact factor: 4.432

8.  Reno-protection of Urine-derived Stem Cells in A Chronic Kidney Disease Rat Model Induced by Renal Ischemia and Nephrotoxicity.

Authors:  Chao Zhang; Sunil K George; Rongpei Wu; Parth Udayan Thakker; Mehran Abolbashari; Tae-Hyoung Kim; In Kap Ko; Yuanyuan Zhang; Yinghao Sun; John Jackson; Sang Jin Lee; James J Yoo; Anthony Atala
Journal:  Int J Biol Sci       Date:  2020-01-01       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.